Get started
Author

Manuel Dómine

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
2022 · Marta Casarrubios, Mariano Provencio, et al. · Journal for ImmunoTherapy of Cancer · 71
SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015
2015 · R. García-Campelo, R. Bernabé, et al. · Clinical & Translational Oncology · 55
PDF
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
2021 · Raquel Laza‐Briviesca, Alberto Cruz‐Bermúdez, et al. · Clinical and Translational Medicine · 52
Predictors of Long-Term Survival in Patients with Lung Cancer Included in the Randomized Spanish Lung Cancer Group 0008 Phase II Trial Using Concomitant Chemoradiation with Docetaxel and Carboplatin plus Induction or Consolidation Chemotherapy
2009 · Pilar Garrido, Rafael Rosell, et al. · Clinical Lung Cancer · 20
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer
2024 · Edurne Arriola, Javier de Castro, et al. · Clinical Drug Investigation · 18
PDF
BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC
2024 · Mariano Provencio, Lucía Robado de Lope, et al. · Lung Cancer · 10
PDF
Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)
2025 · Belén Sierra Rodero, Cristina Martínez-Toledo, et al. · OncoImmunology · 9
PDF
Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain
2025 · Mariano Provencio, Manuel Cobo, et al. · The Lancet Regional Health - Europe · 4
MA01.08 Five-Year Clinical Outcomes of Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer (NADIM Trial)
2024 · M. Provencio, E. Nadal, et al. · Journal of Thoracic Oncology · 3
PDF
Eritema acral inducido por quimioterapia. Descripción de cuatro casos y revisión de la literatura.
1998 · Ma Carmen Fariña, Jesús Alberto Andrade, et al. · Actas Dermo-Sifiliográficas · 3
Linguistic adaptation and validation of the Spanish version of the Memorial Pain Assessment Card (MPAC)
2009 · Yolanda Escobar, Manuel Domine, et al. · Clinical & Translational Oncology · 2
Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial
2026 · Ross A Soo, Sanjay Popat, et al. · The Lancet Respiratory Medicine
Clinical Characteristics and Survival Outcomes in Patients With Small Cell Lung Cancer in Spain: An Analysis of the Thoracic Tumor Registry (2016–2025)
2026 · Cristina Candal-Pedreira, Alberto Ruano-Ravina, et al. · Archivos de Bronconeumología
ARIAN protocol: a phase III study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer
2026 · Mariano Provencio, David Aguiar, et al. · Expert Opinion on Biological Therapy
P3.08E.04 TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials
2024 · C. Martínez-Toledo, B. Sierra, et al. · Journal of Thoracic Oncology
PDF
Effects of 5-fluorouracil on endothelial nitric oxide synthase in endothelial cells in different states of confluence
2004 · V. M. Casado-Echarren, C. Abarrategui, et al. · Journal of Clinical Oncology
Works count: 17
Citation count: 247
H-index: 7
I10-index: 6
Year
Topic
Type